Fig. 3 | Scientific Reports

Fig. 3

From: Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study

Fig. 3

Subgroup analysis for lung infection and fibrosis. Risk of other lung conditions includes (A) influenza and pneumonia, (B) acute lower lung infection, (C) suppurative lung disease, and (D) pulmonary fibrosis in GLP-1 RA users versus DPP4i users. The vertical line indicates an HR of 1.00. A lower limit of the 95% CI greater than 1.00 indicates a significantly higher risk. GLP1-RA glucagon-like peptide-1 receptor agonist, DPP4i dipeptidyl peptidase-4 inhibitor, HR hazard ratio, CI confidence interval, BMI body mass index, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin.

Back to article page